Henry G Bone
Overview
Explore the profile of Henry G Bone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
3470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watts N, Bilezikian J, Bone H, Clarke B, Denham D, Levine M, et al.
J Endocr Soc
. 2023 Apr;
7(5):bvad043.
PMID: 37091306
Context: Chronic hypoparathyroidism is conventionally treated with oral calcium and active vitamin D to reach and maintain targeted serum calcium and phosphorus levels, but some patients remain inadequately controlled. Objective:...
2.
Miller P, Bilezikian J, Fitzpatrick L, Mitlak B, McCloskey E, Cosman F, et al.
Curr Med Res Opin
. 2020 Sep;
36(11):1861-1872.
PMID: 32969719
Objective: Fractures due to osteoporosis represent a serious burden on patients and healthcare systems. The objective of this review is to provide an overview of the anabolic agent abaloparatide (ABL)...
3.
Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M, et al.
J Clin Endocrinol Metab
. 2018 May;
103(8):2949-2957.
PMID: 29800372
Purpose: In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO). Methods:...
4.
McClung M, Brown J, Diez-Perez A, Resch H, Caminis J, Meisner P, et al.
J Bone Miner Res
. 2018 Apr;
33(8):1397-1406.
PMID: 29694685
Over 12 months, romosozumab increased bone formation and decreased bone resorption, resulting in increased bone mineral density (BMD) in postmenopausal women with low BMD (NCT00896532). Herein, we report the study...
5.
Bone H, Wagman R, Pannacciulli N, Papapoulos S
Lancet Diabetes Endocrinol
. 2017 Sep;
5(10):768-769.
PMID: 28938993
No abstract available.
6.
Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S, et al.
Lancet Diabetes Endocrinol
. 2017 May;
5(7):513-523.
PMID: 28546097
Background: Long-term safety and efficacy of osteoporosis treatment are important because of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of denosumab, which...
7.
Adachi J, Bone H, Daizadeh N, Dakin P, Papapoulos S, Hadji P, et al.
BMC Musculoskelet Disord
. 2017 Apr;
18(1):174.
PMID: 28449657
Background: Denosumab treatment for up to 8 years in the FREEDOM study and Extension was associated with low fracture incidence. It was not clear whether subjects who discontinued during the...
8.
Watts N, Brown J, Papapoulos S, Lewiecki E, Kendler D, Dakin P, et al.
J Bone Miner Res
. 2017 Mar;
32(7):1481-1485.
PMID: 28277603
Denosumab is a fully human monoclonal antibody against receptor activator of NF-κB ligand (RANKL) that decreases osteoclast formation, function and survival, and is approved for the treatment of postmenopausal women...
9.
Tucci J, Bone H, Su G, Tan M, Ozturk Z, Aftring P
Ther Adv Endocrinol Metab
. 2015 Aug;
6(4):155-62.
PMID: 26301065
Objective: Bisphosphonates are the most effective therapeutic agents in patients with Paget's disease of bone. As a result of their inhibition of osteoclastic activity, hypocalcemia of variable frequency and severity...
10.
Body J, Bone H, De Boer R, Stopeck A, Van Poznak C, Damiao R, et al.
Eur J Cancer
. 2015 Jun;
51(13):1812-21.
PMID: 26093811
Background: This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab. Methods: Laboratory abnormalities and adverse events of hypocalcaemia in patients with metastatic bone...